Review anchor
Hypoxia-inducible factor prolyl hydroxylase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Hypoxia-inducible factor prolyl hydroxylase
CHEMBL3831261
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Hypoxia-inducible factor prolyl hydroxylase as ChEMBL target CHEMBL3831261, mapped to UniProt Q96KS0. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3831261
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96KS0
Prolyl hydroxylase EGLN2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Hypoxia-inducible factor prolyl hydroxylase matters
Hypoxia-inducible factor prolyl hydroxylase is reviewed as Prolyl hydroxylase EGLN2 (UniProt Q96KS0); Hypoxia-inducible factor prolyl hydroxylase shows approved-linked disease relevance led by anemia (phenotype). 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 23 compounds, and 10 assays, with lead potency reaching pChEMBL 5.6.
Protein context
Prolyl hydroxylase EGLN2
Prolyl hydroxylase EGLN2 Sequence length is 407 aa.
Review this target as Hypoxia-inducible factor prolyl hydroxylase, mapped to UniProt Q96KS0. ChEMBL maps the protein component as Prolyl hydroxylase EGLN2. Sequence length is 407 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q96KS0
Protein
Disease context
anemia (phenotype)
Hypoxia-inducible factor prolyl hydroxylase shows approved-linked disease relevance led by anemia (phenotype). 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DAPRODUSTAT, ROXADUSTAT.
Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include DAPRODUSTAT, ROXADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 23 compounds, and 10 assays for this target. The dominant activity type is EC50. CHEMBL4463388 is the current potency anchor at pChEMBL 5.6.
Use CHEMBL4463388 as the tractability anchor when discussing potency (pChEMBL 5.6).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 5.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Hypoxia-inducible factor prolyl hydroxylase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96KS0, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why anemia (phenotype) is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
23
Total Compounds
10
Total Assays
0
Approved Drugs
EC50: 23.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4463388
|
5.6 | EC50 | — |
|
|
No preferred name
CHEMBL4464252
|
5.6 | EC50 | — |
|
|
No preferred name
CHEMBL4459542
|
5.5 | EC50 | — |
|
|
No preferred name
CHEMBL4519581
|
5.4 | EC50 | — |
|
|
No preferred name
CHEMBL4514184
|
5.3 | EC50 | — |
Source Header